IP Verse

Process For T Cell Expansion - EP2791163

The patent EP2791163 was granted to Allovir on Nov 27, 2024. The application was originally filed on Dec 12, 2012 under application number EP12815750A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2791163

ALLOVIR
Application Number
EP12815750A
Filing Date
Dec 12, 2012
Status
Patent Maintained As Amended
Oct 25, 2024
Grant Date
Nov 27, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANNov 30, 2017MEWBURN ELLISADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2005035728
INTERNATIONAL-SEARCH-REPORTWO2009053109
INTERNATIONAL-SEARCH-REPORTWO2011028531
INTERNATIONAL-SEARCH-REPORTWO2011146473
OPPOSITIONWO2005035728
OPPOSITIONWO2009053109
OPPOSITIONWO2011028531
OPPOSITIONWO2011146473

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Bernhard Hemmer, Takayuki Kondo, Bruno Gran, Clemencia Pinilla, Irene Cortese, Jeannick Pascal, Abraham Tzou, Henry F. Mcfarland, Richard Houghten, Roland Martin, "Minimal peptide length requirements for CD4+ T cell clones—implications for molecular mimicry and T cell survival", International Immunology, Oxford University Press, GB, GB , (20000301), vol. 12, no. 3, doi:10.1093/intimm/12.3.375, ISSN 0953-8178, pages 375 - 383-
OPPOSITION- CHA et al., "IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo", Breast Cancer Res. Treat., (20100000), vol. 122, no. 2, pages 359 - 369-
OPPOSITION- GERDEMANN et al., "Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host", Molecular Therapy, (20090900), vol. 17, no. 9, pages 1616 - 1625-
OPPOSITION- GERDEMANN et al., "Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections", Molecular Therapy, (20120800), vol. 20, no. 8, pages 1622 - 1632-
OPPOSITION- HOBEIKA et al., "Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease", Cytotherapy, (20080000), vol. 10, no. 3, pages 289 - 302-
OPPOSITION- KEIRNAN et al., "T Cell Therapy for Viral Infections after Hematopoietic Stem Cell Transplant", JPT immunology application note, (20120700), pages 1 - 2-
OPPOSITION- KEIRNAN et al., "T Cell Therapy for Viral Infections after Hematopoietic Stem Cell Transplant", JPT immunology application note, (20120700), pages 1 - 2, XP055299950-
OPPOSITION- KOCH et al, "Scrutinizing MHC-I Binding Peptides and Their Limits of Variation (e1003088)", PLOS Computational Biology, (2013), vol. 9, no. 6, doi:10.1371/journal.pcbi.1003088, pages 1 - 9-
OPPOSITION- LAPTEVA et al., "Optimization Manufacture of Virus- and Tumor-Specific T Cells (article ID 434392)", Stem Cells International, (20110000), pages 1 - 8-
OPPOSITION- MIELCAREK et al., "Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells", Blood, (19970301), vol. 89, no. 5, pages 1629 - 1634-
OPPOSITION- MIELCAREK et al., "Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells", Blood, (19970301), vol. 89, no. 5, pages 1629 - 1634, XP055069022-
OPPOSITION- NA et al., "Human Bone Marrow as a Source of Multifunctional CMV-Specific CD4+ T Cells for Adoptive Cell Therapy", Blood, (20070000), vol. 110, XP055439297-
OPPOSITION- REDCHENKO et al., "Accessing Epstein-Barr Virus-Specific T-Cell Memory with Peptide-Loaded Dendritic Cells", J. Virol, (19990100), vol. 73, no. 1, pages 334 - 342-
OPPOSITION- REDCHENKO et al., "Accessing Epstein-Barr Virus-Specific T-Cell Memory with Peptide-Loaded Dendritic Cells", J. Virol, (19990100), vol. 73, no. 1, pages 334 - 342, XP055329245-
OPPOSITION- REYES et al., "Granulocyte colony-stimulation factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response", British Journal of Cancer, (19990000), vol. 80, no. 1/2, pages 229 - 235-
OPPOSITION- REYES et al., "Granulocyte colony-stimulation factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response", British Journal of Cancer, (19990000), vol. 80, no. 1/2, pages 229 - 235, XP055439317-
OPPOSITION- ROONEY et al., "Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials", Molecular Therapy - Nucleic acids, (20120000), vol. 1-
OPPOSITION- TEAGUE et al., "Interleukin-IS rescues tolerant CDs+ T cells for use in adoptive immunotherapy of established tumors", Nature Medicine, (20060000), vol. 12, no. 3, pages 335 - 341, XP055576394-
OPPOSITION- CHA et al., "IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo", Breast Cancer Res. Treat., (20100000), vol. 122, no. 2, pages 359 - 369, XP036008958
OPPOSITION- GERDEMANN et al., "Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host", Molecular Therapy, (20090900), vol. 17, no. 9, pages 1616 - 1625, XP055050633
OPPOSITION- GERDEMANN et al., "Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma", Molecular Therapy, (20111200), vol. 19, no. 12, pages 2258 - 2268, XP008154173
OPPOSITION- GERDEMANN et al., "Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections", Molecular Therapy, (20120800), vol. 20, no. 8, pages 1622 - 1632, XP055034394
OPPOSITION- ROONEY et al., "Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials", Molecular Therapy - Nucleic acids, (20120000), vol. 1, XP055439328
OPPOSITION- HOBEIKA et al., "Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease", Cytotherapy, (20080000), vol. 10, no. 3, pages 289 - 302, XP055439305
OPPOSITION- VERA et al., "Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)", NIH Public Access, Author Manuscript, Journal of Immunotherapy, (20110401), pages 1 - 19, XP055031297
OPPOSITION- GERDEMANN et al., "Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant", Journal of Visualized Experiments, (20110500), vol. 51, no. e2736, pages 1 - 6, XP055034564
OPPOSITION- DUNNE et al., "Selective Expansion and Partial Activation of Human NK Cells and NK Receptor-Positive T Cells by IL-2 and IL-15", The Journal of Immunology, (20010000), vol. 167, no. 6, pages 3129 - 3138, XP055221094
OPPOSITION- LAPTEVA et al., "Optimization Manufacture of Virus- and Tumor-Specific T Cells", Stem Cells International, (20110000), pages 1 - 8, XP055031037

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents